Targeting of Beta Adrenergic Receptors Results in Therapeutic Efficacy against Models of Hemangioendothelioma and Angiosarcoma

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Stiles, Jessica M ^a   Amaya, Clarissa ^a   Rains, Steven ^a   Diaz, Dolores ^a   Pham, Robert ^b   Battiste, James ^c   Modiano, Jaime F ^d   Kokta, Victor ^e   Boucheron, Laura E ^b   Mitchell, Dianne C ^a   Bryan, Brad A ^a  

^a Paul L Foster School of Medicine   (United States)

^b New Mexico State University   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROPRANOLOL;

ANGIOSARCOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE REGULATION; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; FEMALE; GENE EXPRESSION; GROWTH INHIBITION; HEMANGIOENDOTHELIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; UNINDEXED SEQUENCE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYTOSKELETON; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HEMANGIOENDOTHELIOMA; HEMANGIOSARCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; PROPRANOLOL; RECEPTORS, ADRENERGIC, BETA;

EID: 84875542929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060021     Document Type: Article

References (33)

1. Hasegawa H, Saiki I, (2002) Psychosocial stress augments tumor development through beta-adrenergic activation in mice. Jpn J Cancer Res 93: 729-735.
2. Veksler IG, Riabukha VN, Smelkova MI, Balitskii KP, (1984) [Changes in the metastasis of experimental tumors and in the antimetastatic effect of cytostatics in their pharmacological action on adrenergic processes]. Eksp Onkol 6: 50-53.
3. Palm D, Lang K, Niggemann B, Drell TLt, Masur K, et al. (2006) The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 118: 2744-2749.
4. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, et al. (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70: 7042-7052.
5. Glasner A, Avraham R, Rosenne E, Benish M, Zmora O, et al. (2010) Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 184: 2449-2457.
6. De Giorgi V, Gandini S, Grazzini M, Benemei S, Marchionni N, et al. (2012) [beta-blockers: a new and emerging treatment for melanoma]. Recenti Prog Med 103: 11-16.
7. Campbell JP, Karolak MR, Ma Y, Perrien DS, Masood-Campbell SK, et al. (2012) Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol 10: e1001363.
8. Szewczyk M, Richter C, Briese V, Richter DU, (2012) A retrospective in vitro study of the impact of anti-diabetics and cardioselective pharmaceuticals on breast cancer. Anticancer Res 32: 2133-2138.
9. Perez Pinero C, Bruzzone A, Sarappa MG, Castillo LF, Luthy IA, (2012) Involvement of alpha2- and beta2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. Br J Pharmacol 166: 721-736.
10. Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, et al. (2011) Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2: 797-809.
11. Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, et al. (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1: 628-638.
12. Slotkin TA, Zhang J, Dancel R, Garcia SJ, Willis C, et al. (2000) Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 60: 153-166.
13. Powe DG, Voss MJ, Habashy HO, Zanker KS, Green AR, et al. (2011) Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat 130: 457-463.
14. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, et al. (2008) Propranolol for severe hemangiomas of infancy. N Engl J Med 358: 2649-2651.
15. Chisholm KM, Chang KW, Truong MT, Kwok S, West RB, et al. (2012) beta-Adrenergic receptor expression in vascular tumors. Mod Pathol 25: 1446-51.
16. Chiu YE, Drolet BA, Blei F, Carcao M, Fangusaro J, et al. (2012) Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer 59: 934-938.
17. Hermans DJ, van Beynum IM, van der Vijver RJ, Kool LJ, de Blaauw I, et al. (2011) Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment. J Pediatr Hematol Oncol 33: e171-173.
18. Morais P, Magina S, Mateus M, Trindade E, Jesus JM, et al. (2011) Efficacy and safety of propranolol in the treatment of parotid hemangioma. Cutan Ocul Toxicol 30: 245-248.
19. Sarialioglu F, Erbay A, Demir S, (2010) Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-alpha therapy. Pediatr Blood Cancer 55: 1433-1434.
20. Avagyan S, Klein M, Kerkar N, Demattia A, Blei F, et al. (2013) Propranolol As A First-Line Treatment For Diffuse Infantile Hepatic Hemangioendothelioma: Case Report And Review Of Literature. J Pediatr Gastroenterol NutrIn press.
21. Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG, (2005) A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 11: 241-247.
22. Budd GT, (2002) Management of angiosarcoma. Curr Oncol Rep 4: 515-519.
23. Mentzel T, Beham A, Calonje E, Katenkamp D, Fletcher CD, (1997) Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases. Am J Surg Pathol 21: 363-374.
24. Mosoia L, Mabrut JY, Adham M, Boillot O, Ducerf C, et al. (2008) Hepatic epithelioid hemangioendothelioma: long-term results of surgical management. J Surg Oncol 98: 432-437.
25. Tamburini BA, Trapp S, Phang TL, Schappa JT, Hunter LE, et al. (2009) Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. PLoS One 4: e5549.
26. Stiles J, Amaya C, Pham R, Rowntree RK, Lacaze M, et al. (2012) Propranolol treatment of infantile hemangioma endothelial cells: A molecular analysis. Exp Ther Med 4: 594-604.
27. Lichtenstein N, Geiger B, Kam Z, (2003) Quantitative analysis of cytoskeletal organization by digital fluorescent microscopy. Cytometry A 54: 8-18.
28. Street CA, Routhier AA, Spencer C, Perkins AL, Masterjohn K, et al. (2010) Pharmacological inhibition of Rho-kinase (ROCK) signaling enhances cisplatin resistance in neuroblastoma cells. Int J Oncol 37: 1297-1305.
29. Arbiser JL, Bingaman A, Durham M, Cowan S, Cohen C, et al. (2002) SVR angiosarcomas can be rejected by CD4 costimulation dependent and CD8 costimulation independent pathways. Mol Med 8: 551-558.
30. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, et al. (2009) Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27: 3154-3160.
31. Park MS, Ravi V, Araujo DM, (2010) Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol 22: 351-355.
32. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, et al. (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27: 3133-3140.
33. Singh H, Tahir TA, Alawo DO, Issa E, Brindle NP, (2011) Molecular control of angiopoietin signalling. Biochem Soc Trans 39: 1592-1596.